Company intelligence / Profile preview

Cornerwise

Massachusetts, United Statescornerwise.com ↗

Ownership: Private
Development stage: Other

Overview

Corner Therapeutics has developed a novel dendritic cell hyperactivation platform designed to induce robust and durable memory T-cell responses. The company’s approach is antigen agnostic and aims to provide life-long immunity against cancer and infectious diseases. As of Q2 2024, the company raised $54 million in Series A funding to initiate its first clinical trial in 2025. Grant funding from the Bill & Melinda Gates Foundation supports their infectious disease vaccine programs targeting HIV, influenza, and COVID‑19. No clinical results have been reported yet as all programs are preclinical

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineImmunotherapy (platform-based)Dendritic cell hyperactivation technology (enables multiple modalities, but primarily vaccines and immunotherapies)
Industry: Biotech

Partnerships

Bill & Melinda Gates Foundation (grant support for infectious disease work)

Beyond the preview

Go deeper on Cornerwise.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cornerwise.

Explore the full profile